EP0037422A1 - Prostaglandines et prostacyclines substituees par le fluor - Google Patents
Prostaglandines et prostacyclines substituees par le fluorInfo
- Publication number
- EP0037422A1 EP0037422A1 EP80902203A EP80902203A EP0037422A1 EP 0037422 A1 EP0037422 A1 EP 0037422A1 EP 80902203 A EP80902203 A EP 80902203A EP 80902203 A EP80902203 A EP 80902203A EP 0037422 A1 EP0037422 A1 EP 0037422A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- difluoro
- alkyl
- title compound
- procedure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003180 prostaglandins Chemical class 0.000 title abstract description 21
- 150000003815 prostacyclins Chemical class 0.000 title abstract description 15
- 229940094443 oxytocics prostaglandins Drugs 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 234
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 25
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 13
- -1 prostaglandin compound Chemical class 0.000 claims description 82
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 239000002253 acid Substances 0.000 claims description 32
- 159000000000 sodium salts Chemical class 0.000 claims description 26
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000004423 acyloxy group Chemical group 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims description 6
- 150000001340 alkali metals Chemical class 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 229960001123 epoprostenol Drugs 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 135
- 238000000034 method Methods 0.000 description 133
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 99
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 92
- 239000000243 solution Substances 0.000 description 92
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 84
- 239000000203 mixture Substances 0.000 description 55
- 238000006243 chemical reaction Methods 0.000 description 53
- 235000019439 ethyl acetate Nutrition 0.000 description 51
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 41
- 150000004702 methyl esters Chemical class 0.000 description 39
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 229910001868 water Inorganic materials 0.000 description 35
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 34
- 229910052938 sodium sulfate Inorganic materials 0.000 description 33
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 32
- 150000002596 lactones Chemical class 0.000 description 31
- 239000011541 reaction mixture Substances 0.000 description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 239000003921 oil Substances 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- 239000007832 Na2SO4 Substances 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 239000010410 layer Substances 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 239000002904 solvent Substances 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 17
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 16
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000012267 brine Substances 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 13
- 150000002373 hemiacetals Chemical class 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 11
- 239000007795 chemical reaction product Substances 0.000 description 11
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 239000002024 ethyl acetate extract Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000012259 ether extract Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- CWXOAQXKPAENDI-UHFFFAOYSA-N sodium methylsulfinylmethylide Chemical compound [Na+].CS([CH2-])=O CWXOAQXKPAENDI-UHFFFAOYSA-N 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- CBLJBAMYHQOPFV-WEVREMHOSA-N (5z)-5-[(4s,5s,6as)-6,6-difluoro-5-hydroxy-4-[(3s)-3-hydroxyoct-1-ynyl]-3a,4,5,6a-tetrahydro-3h-cyclopenta[b]furan-2-ylidene]pentanoic acid Chemical compound O1\C(=C/CCCC(O)=O)CC2[C@@H](C#C[C@@H](O)CCCCC)[C@H](O)C(F)(F)[C@H]21 CBLJBAMYHQOPFV-WEVREMHOSA-N 0.000 description 6
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 6
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical compound O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 description 6
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- KVLKYYAZTBWZDN-UHFFFAOYSA-N ethyl 4,4-difluoro-5-oxopentanoate Chemical compound CCOC(=O)CCC(F)(F)C=O KVLKYYAZTBWZDN-UHFFFAOYSA-N 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 4
- 239000004593 Epoxy Substances 0.000 description 4
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 4
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 4
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000012063 pure reaction product Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- JICFSEVPEYNTTG-UHFFFAOYSA-N 3,3-difluorooxane-2,6-dione Chemical compound FC1(F)CCC(=O)OC1=O JICFSEVPEYNTTG-UHFFFAOYSA-N 0.000 description 3
- TZFZWMGDQIFYDE-UHFFFAOYSA-N 4,4-difluoro-5-methoxy-5-oxopentanoic acid Chemical compound COC(=O)C(F)(F)CCC(O)=O TZFZWMGDQIFYDE-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- LOGSONSNCYTHPS-UHFFFAOYSA-N cyclopentane-1,3-dione Chemical compound O=C1CCC(=O)C1 LOGSONSNCYTHPS-UHFFFAOYSA-N 0.000 description 3
- YVPKMLFMDHSTKJ-UHFFFAOYSA-N diethyl 2,2-difluoropentanedioate Chemical compound CCOC(=O)CCC(F)(F)C(=O)OCC YVPKMLFMDHSTKJ-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 3
- 150000004072 triols Chemical class 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- RTCUCQWIICFPOD-SECBINFHSA-N (1r)-1-naphthalen-1-ylethanamine Chemical compound C1=CC=C2C([C@H](N)C)=CC=CC2=C1 RTCUCQWIICFPOD-SECBINFHSA-N 0.000 description 2
- RTCUCQWIICFPOD-VIFPVBQESA-N (1s)-1-naphthalen-1-ylethanamine Chemical compound C1=CC=C2C([C@@H](N)C)=CC=CC2=C1 RTCUCQWIICFPOD-VIFPVBQESA-N 0.000 description 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 2
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 2
- RTCUCQWIICFPOD-UHFFFAOYSA-N 1-naphthalen-1-ylethanamine Chemical compound C1=CC=C2C(C(N)C)=CC=CC2=C1 RTCUCQWIICFPOD-UHFFFAOYSA-N 0.000 description 2
- SZNYYWIUQFZLLT-UHFFFAOYSA-N 2-methyl-1-(2-methylpropoxy)propane Chemical compound CC(C)COCC(C)C SZNYYWIUQFZLLT-UHFFFAOYSA-N 0.000 description 2
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 2
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 2
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 2
- CPVNCBJFUQQXSU-UHFFFAOYSA-N 5-triphenylphosphaniumylpentanoate Chemical compound C1(=CC=CC=C1)[P+](CCCCC(=O)[O-])(C1=CC=CC=C1)C1=CC=CC=C1 CPVNCBJFUQQXSU-UHFFFAOYSA-N 0.000 description 2
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 2
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 2
- 229910010082 LiAlH Inorganic materials 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 229910003251 Na K Inorganic materials 0.000 description 2
- STJFYCWYHROASW-UHFFFAOYSA-N O-methyl-glaucamine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C2OC(OC)C3=C4OCOC4=CC=C3C12 STJFYCWYHROASW-UHFFFAOYSA-N 0.000 description 2
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 229910019020 PtO2 Inorganic materials 0.000 description 2
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 2
- JVKRJRMNBWGRIA-UHFFFAOYSA-N [O-]C(CCC(C[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)(F)F)=O.Cl Chemical compound [O-]C(CCC(C[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)(F)F)=O.Cl JVKRJRMNBWGRIA-UHFFFAOYSA-N 0.000 description 2
- UOCVCBMHGQZKJD-UHFFFAOYSA-N [O-]C(CCCC(F)[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)=O Chemical compound [O-]C(CCCC(F)[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)=O UOCVCBMHGQZKJD-UHFFFAOYSA-N 0.000 description 2
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2
- FDSGHYHRLSWSLQ-UHFFFAOYSA-N dichloromethane;propan-2-one Chemical compound ClCCl.CC(C)=O FDSGHYHRLSWSLQ-UHFFFAOYSA-N 0.000 description 2
- JGHYBJVUQGTEEB-UHFFFAOYSA-M dimethylalumanylium;chloride Chemical compound C[Al](C)Cl JGHYBJVUQGTEEB-UHFFFAOYSA-M 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000011491 glass wool Substances 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- JOFQXJHXMHCMIO-UHFFFAOYSA-N methyl 4,4-difluoro-5-hydroxypentanoate Chemical compound COC(=O)CCC(F)(F)CO JOFQXJHXMHCMIO-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000004533 oil dispersion Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- XHFXMNZYIKFCPN-UHFFFAOYSA-N perchloryl fluoride Chemical compound FCl(=O)(=O)=O XHFXMNZYIKFCPN-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 2
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- GTCOTWNVKUCYJX-RFPGKLGKSA-N (1R,2R,4R,5S)-3,3-difluoro-2,5-dihydroxy-4-iodo-2-methylcyclopentane-1-carboxylic acid Chemical compound FC1([C@@]([C@@H]([C@@H]([C@H]1I)O)C(=O)O)(O)C)F GTCOTWNVKUCYJX-RFPGKLGKSA-N 0.000 description 1
- WREYQRASYBTETA-FVJIAFLCSA-N (1S,2S,3R,5R)-1,2,4,4-tetrafluoro-3-hydroxy-3-methyl-6-oxabicyclo[3.1.0]hexane-2-carboxylic acid Chemical compound FC1([C@@]([C@@]([C@]2([C@H]1O2)F)(C(=O)O)F)(O)C)F WREYQRASYBTETA-FVJIAFLCSA-N 0.000 description 1
- FFPRUECWDUUDBZ-ARQDHWQXSA-N (1r,3s,4s,5r)-2,2-difluoro-4-(2-hydroxyethyl)-6-oxabicyclo[3.1.0]hexan-3-ol Chemical compound FC1(F)[C@@H](O)[C@H](CCO)[C@H]2O[C@H]21 FFPRUECWDUUDBZ-ARQDHWQXSA-N 0.000 description 1
- YHORBTDAOVFXHU-OALUTQOASA-N (1s,2s)-1-(1,1-difluorohept-6-ynyl)-2-octylcyclopentane Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1C(F)(F)CCCCC#C YHORBTDAOVFXHU-OALUTQOASA-N 0.000 description 1
- FFPRUECWDUUDBZ-AZGQCCRYSA-N (1s,3r,4r,5s)-2,2-difluoro-4-(2-hydroxyethyl)-6-oxabicyclo[3.1.0]hexan-3-ol Chemical compound FC1(F)[C@H](O)[C@@H](CCO)[C@@H]2O[C@@H]21 FFPRUECWDUUDBZ-AZGQCCRYSA-N 0.000 description 1
- FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- MNOKQWHLXZMUET-OALUTQOASA-N (3s,4s)-1,1-difluoro-3-hept-6-ynyl-4-octylcyclopentane Chemical compound CCCCCCCC[C@H]1CC(F)(F)C[C@@H]1CCCCCC#C MNOKQWHLXZMUET-OALUTQOASA-N 0.000 description 1
- AJUOHKIAWOIZJL-HLRBRJAUSA-N (3s,4s)-1,1-difluoro-3-hept-6-ynyl-4-octylcyclopentane;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CCCCCCCC[C@H]1CC(F)(F)C[C@@H]1CCCCCC#C AJUOHKIAWOIZJL-HLRBRJAUSA-N 0.000 description 1
- DVGBAPCQZLELER-ROUUACIJSA-N (3s,4s)-3-(1,1-difluorohept-6-ynyl)-1,1-difluoro-4-octylcyclopentane Chemical compound CCCCCCCC[C@H]1CC(F)(F)C[C@@H]1C(F)(F)CCCCC#C DVGBAPCQZLELER-ROUUACIJSA-N 0.000 description 1
- LXHHHJURALGCPW-UHFFFAOYSA-N (5-bromo-5-oxopentyl)-triphenylphosphanium Chemical compound C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)Br)C1=CC=CC=C1 LXHHHJURALGCPW-UHFFFAOYSA-N 0.000 description 1
- MGUQYZSKPMBDBI-UHFFFAOYSA-N 1,2,3,5a,6,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound N1CCC=CC2CCCCN21 MGUQYZSKPMBDBI-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- SSSAHVJVVZSZQL-UHFFFAOYSA-N 1-bromo-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Br)C(=O)NC1=O SSSAHVJVVZSZQL-UHFFFAOYSA-N 0.000 description 1
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 description 1
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 description 1
- TVWWMKZMZALOFP-UHFFFAOYSA-N 2,2-dichloroethenone Chemical compound ClC(Cl)=C=O TVWWMKZMZALOFP-UHFFFAOYSA-N 0.000 description 1
- PIVAHSCRTJPWJU-UHFFFAOYSA-N 2,2-difluoropentanedioic acid Chemical compound OC(=O)CCC(F)(F)C(O)=O PIVAHSCRTJPWJU-UHFFFAOYSA-N 0.000 description 1
- SQRDAIHXBDTZFG-UHFFFAOYSA-N 2,3-difluoro-2,5-dihydroxy-4-iodo-3-methylcyclopentane-1-carboxylic acid Chemical compound CC1(F)C(I)C(O)C(C(O)=O)C1(O)F SQRDAIHXBDTZFG-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- FQHWQFIPEVBFKT-UHFFFAOYSA-N 2-[5-[cyclopropylmethyl(1,2-dihydroacenaphthylen-5-yl)amino]-3-methoxypyridine-2-carbonyl]cyclopropane-1-carboxylic acid Chemical compound C1(CC1)CN(C=1C=C(C(=NC=1)C(=O)C1C(C1)C(=O)O)OC)C1=CC=C2CCC=3C=CC=C1C=32 FQHWQFIPEVBFKT-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- RDVQCZWYQQOQOC-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 RDVQCZWYQQOQOC-UHFFFAOYSA-N 0.000 description 1
- ZTXWCIWMKJOURT-UHFFFAOYSA-N 5,5-difluorocyclopenta-1,3-diene Chemical compound FC1(F)C=CC=C1 ZTXWCIWMKJOURT-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229930184489 Iodoether Natural products 0.000 description 1
- DJOWTWWHMWQATC-KYHIUUMWSA-N Karpoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1(O)C(C)(C)CC(O)CC1(C)O)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C DJOWTWWHMWQATC-KYHIUUMWSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- 229910004809 Na2 SO4 Inorganic materials 0.000 description 1
- ACDCWEXHTRWMQI-ODTYPEPTSA-N O[C@@H]1C([C@@H]([C@H]([C@H]1C(=O)O)O)I)C(F)F Chemical compound O[C@@H]1C([C@@H]([C@H]([C@H]1C(=O)O)O)I)C(F)F ACDCWEXHTRWMQI-ODTYPEPTSA-N 0.000 description 1
- PTKYYYPGWZJHMH-WQNBZEEGSA-N O[C@@H]1C([C@H]2[C@H]([C@H]1C(=O)O)O2)C(F)F Chemical compound O[C@@H]1C([C@H]2[C@H]([C@H]1C(=O)O)O2)C(F)F PTKYYYPGWZJHMH-WQNBZEEGSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- NXTVJHPFCDHRIA-UHFFFAOYSA-N [O-]C(CCC(C(F)[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)(F)F)=O Chemical compound [O-]C(CCC(C(F)[P+](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)(F)F)=O NXTVJHPFCDHRIA-UHFFFAOYSA-N 0.000 description 1
- ZXPJBQLFCRVBDR-UHFFFAOYSA-N acetic acid;methanesulfonic acid Chemical compound CC(O)=O.CS(O)(=O)=O ZXPJBQLFCRVBDR-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000006241 alcohol protecting group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N anhydrous diethylene glycol Natural products OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- GUNJVIDCYZYFGV-UHFFFAOYSA-K antimony trifluoride Chemical compound F[Sb](F)F GUNJVIDCYZYFGV-UHFFFAOYSA-K 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- NGRAIMFUWGFAEM-UHFFFAOYSA-N diethyl 2-oxopentanedioate Chemical compound CCOC(=O)CCC(=O)C(=O)OCC NGRAIMFUWGFAEM-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- IAURJAZOQMEKRP-UHFFFAOYSA-N ethyl 4,4-difluoro-5-hydroxypentanoate Chemical compound CCOC(=O)CCC(F)(F)CO IAURJAZOQMEKRP-UHFFFAOYSA-N 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- VSHDHKDWBUMJIJ-UHFFFAOYSA-N iodo hypoiodite Chemical class IOI VSHDHKDWBUMJIJ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910001507 metal halide Inorganic materials 0.000 description 1
- 150000005309 metal halides Chemical class 0.000 description 1
- BDGDWWGTAFXEEW-UHFFFAOYSA-N methylsulfinylmethane;oxalyl dichloride Chemical compound CS(C)=O.ClC(=O)C(Cl)=O BDGDWWGTAFXEEW-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- WURFKUQACINBSI-UHFFFAOYSA-M ozonide Chemical compound [O]O[O-] WURFKUQACINBSI-UHFFFAOYSA-M 0.000 description 1
- 238000005949 ozonolysis reaction Methods 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- WJCXADMLESSGRI-UHFFFAOYSA-N phenyl selenohypochlorite Chemical compound Cl[Se]C1=CC=CC=C1 WJCXADMLESSGRI-UHFFFAOYSA-N 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- XRBCRPZXSCBRTK-UHFFFAOYSA-N phosphonous acid Chemical class OPO XRBCRPZXSCBRTK-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001110 prostacyclinlike Effects 0.000 description 1
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 238000006894 reductive elimination reaction Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-N selenous acid Chemical compound O[Se](O)=O MCAHWIHFGHIESP-UHFFFAOYSA-N 0.000 description 1
- 150000003962 selenoxides Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- UYCAUPASBSROMS-AWQJXPNKSA-M sodium;2,2,2-trifluoroacetate Chemical compound [Na+].[O-][13C](=O)[13C](F)(F)F UYCAUPASBSROMS-AWQJXPNKSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- QHMQWEPBXSHHLH-UHFFFAOYSA-N sulfur tetrafluoride Chemical compound FS(F)(F)F QHMQWEPBXSHHLH-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/62—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by introduction of halogen; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/48—Halogenated derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/14—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
- C07D307/937—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans with hydrocarbon or substituted hydrocarbon radicals directly attached in position 2, e.g. prostacyclins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5407—Acyclic saturated phosphonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Definitions
- This invention relates to and has as its objective the production of pharmacologically active prostaglandin and prostacyclin compounds which possess a chemical structure whereby they are fluorine substituted in any one or more of the following positions on the molecule 4,4; 7,7; 10,10; and 5,
- prostaglandin and prostacyclin compounds are those organic compounds possessing generic chemical structures which may be characterized as possessing the following basic skeletal structural formulae derived from prostanoic acid:
- the compounds of this invention may be generically characterized as prostaglandin and prostacyclin compounds whose chemical structures from the C 4 to C 12 positions of the molecule may be represented by the following formulae:
- the remaining positions of the molecule of the respective prostaglandin and prostacyclin compounds of this invention may be comprised of those substituents as are well known to and understood by the skilled worker, as more specifically set forth hereinafter, More particularly, it is a specific objective of this invention to produce useful prostaglandin and prostacyclin compounds possessing chemical structural configurations from the C 4 to C 12 positions which may be represented by the following formulae:
- Y,X,T and W may be H or F, with the proviso that at least one of Y,X,T and W must be F; and wherein V may be H, OH, acyloxy and alkoxy.
- this invention relates to the production of prostaglandin and prostacyclin compounds possessing the following general chemical structures:
- Y, T, W, and X may each be H or F; provided that at least one of Y, T, W, and X is F;
- L may be any side chain which is known in the art to be part of and incorporable in the respective prostaglandin or prostacyclin compound involved, for example, those side chains which are disclosed and taught to the skilled worker in Belgian Patent 851,122, U.S. Patent 4,110,532, U.S. Patent 4,158,667, U.S. Patent 4,191,824, U.S. Patent 4,124,599 and U,S, Patent 4,174,441 to be possible to incorporate in the said compounds, the teachings and disclosures of which patents are incorporated herein by specific reference thereto;
- Z may also be any side chain which is known in the art to be part of and be possible of incorporation in the respective prostaglandin or prostacyclin compound involved, for example, those side chains which are disclosed and taught to the skilled worker in Belgian Patent 851,122, U.S. Patent 4,110,532, U.S. Patent 4,124,599, U.S. Patent 4,158,667, U.S. Patent 4,191,824, and U.S.
- Patent 4,174,441 to be possible to incorporate in the said compounds, the teachings and disclosures of which patents are incorporated herein by specific reference; and V may also be any substituent which is known in the art and by the skilled worker to be present at those positions in prostaglandin and prostacyclin compounds as is taught and disclosed to the skilled worker by various prior art publications, such as Belgian Patent 851,122, U.S. Patent 4,110,532, U.S. Patent 4,124,500, U.S. Patent 4,158,667, U.S. Patent 4,191,824, and U.S. Patent 4,174,441, which teachings and disclosures are incorporated hereby by specific reference.
- V may be hydrogen, hydroxy, acyloxy, lower alkoxy, hydroxy lower alkyl, or oxo
- Z may be -Z 1 -E, wherein Z 1 is (CH 2 ) -CH 2 ----CH 2 , or - (CH 2 ) -O-CH 2 - , or 2 g / 2 ⁇ g ⁇ -•
- X 1 is hydrogen, alkyl, cycloalkyl, aralkyl, phenyl, phenyl substituted with chloro or alkyl, an alkali metal or a substituted ammonium cation; or -CH 2 OH; o
- L 2 or L 3 are hydrogen, alkyl or
- L 4 is a) amino of the formula -NR 21 R 22 , wherein R 21 and R 22 are hydrogen, alkyl of 1 to 12 carbon atoms inclusive aralkyl of 7 to 12 carbon atoms inclusive, phenyl, phenyl substituted with 1,2 or 3 chloro or alkyl substituents of 1 to 3 carbon atoms inclusive, or phenyl substituted with hydroxy carbonyl or alkoxy carbonyl of 1 to 4 carbon atoms inclusive; or b) carbonylamino of the formula -NR 23 COR 21 , wherein R restroom, is hydrogen or alkyl of 1 to 4 carbon atoms and R 21 is as defined above; or c) sulfonylamino of the formula -NR 23 S0 2 R 21 , wherein R restroom. and R-., are as defined above; or
- L 5 is p-substituted phenyl selected from the group consisting of:
- R 24 is methyl, phenyl, acetamidophenyl, benzamidophenyl or -NH 2 ;
- R 25 is methyl, phenyl, -NH 2 , or methoxy; and
- R 26 is hydrogen or acetamido;
- R 3 and R 4 may be H, OH, alkoxy, acyloxy, or fluoro with the proviso that one of R 3 and R 4 is fluoro only when the other is fluoro or hydrogen and when taken together R 3 and R 4 is oxo; and R 7 may be a) -(CH 2 ) g -CH- 3 , wherein g is 3, 4 or.5;
- R 20 is lower alkyl, lower alkenyl, aralkyl or substituted aralkyl; M, Q, V, W, X, Y and T are as hereinbefore defined.
- a 1 is Y, W, X and T are H or F; Q is H; R 30 is H or F 20 is lower alkyl; V is H or OH; and M is OR., wherein R. is lower alkyl or an alkali metal, for example, sodium.
- the compounds of this invention are physiologically active compounds which possess prostacyclin-like activity.
- the products of this invention may be employed for the purpose of lowering elevated blood pressure and of increasing peripheral blood flow. Therefore, the products of this invention . may be employed in the treatment of hypertension or for the relief of circulatory problems.
- the compounds of this invention prevent the aggregation of blood platelets thereby removing one of the contributory factors to the formation of atherosclerotic plaques.
- the products of this invention may be employed prophylactically in patients with a tendency of coronary infarcts.
- the products of this invention may be employed in hemodialysis and during open heart surgery where it is important to prevent aggregation of platelets thereby impeding the flow of blood through the filter pads.
- some of the products of this invention cause regression of the corpus luteum, and they can therefore be used for estrus synchronization in farm animals so as to achieve greater economy in the practice of artificial insemination, or as contraceptive agents in the human female. Being protected from metabolic inactivation these compounds can be administered perorally or intravenously, in contrast to the corresponding natural prostaglandins.
- some of the products of this invention have been found to be resistant to the action of the major prostaglandin inactivating enzyme, 15-hydroxy- prostaglandin dehydrogenase. Such failure to be destroyed in the body has the effect of prolonging or enhancing the action of these substances when compared with the naturally occurring prostaglandins.
- one of the most important properties of the products of this invention is the considerable chemical stability which is imparted to them by the presence of the fluorine substitutents the 4,4; 7 ,7; 10,10; or 5 positions. As a result of this greatly increased chemical stability the products of this invention retain their biological activity considerably longer than is the case with the naturally occurring prostacyclins .
- the pharmacologically active compounds of this invention may be administered to the animal or patient being treated therewith in any manner known and convenient to the skilled worker practicing the invention, the dosage and concentration of the final products being adjusted to the requirement of the patient and the properties of the respective compound being employed.
- the skilled worker may prepare the final products in such compositions and dosage forms as are usually employed for such purposes, depending upon the route of administration selected for the ultimate composition, for example, parenteral, peroral or topical final dosage and routes of administration.
- R ' ,X', and M ' are as defined herein .
- cyclopentane-1, 3-dione is converted into the isobutyl ether with isobutanol and a strong acid such as p-tolunesulfonic acid.
- the resultant racemic enol ether may than be further treated in accordance with this invention with allyl bromide in the presence of a strong base such as lithium diisopropylamide to yield the allyl derivative which is hydrolyzed with a mineral acid such as HC1 and the hydrolysis product (lIb) treated with perchloryl fluoride in the presence of potassium bicarbonate.
- the intermediate difluoro derivative resulting from this reaction is not isolated but immediately reduced with a hydride reducing agent such as potassium tri-sec-butylborohydride to form the difluoro diol (III).
- a hydride reducing agent such as potassium tri-sec-butylborohydride
- This compound is subjected to ozonolysis followed by reductive cleavage of the ozonide, the reducing agent selected being, for example, dimethyl sulfide.
- the resolution of the lactone (V) involves hydrol- ysis of the latter with a base, such as potassium hydroxide, by the reaction of the resultant salt with optically active ⁇ - (1-naphthyl) -ethylamine yielding crystalline salts which are recrystallized to constant specific rotation and then treated with a base to decompose the salts and to remove the ⁇ - (1-naphthyl) - ethylamine by extraction with ether.
- the resultant optically active salts are then directly converted into the iodo lactones (Via) and VIb) by treatment with iodine and dilute KOH.
- the resultant iodo lactones may then be carried forward by the process of this invention either in optically active form or as the racemate, which latter alternative is shown in the center of the formula charts.
- the iodo lactone (VI) are then converted into the epoxy lactones (VII) by treatment with base followed by mild acid treatment. Some of the resultant epoxy acid which fails to lactonize is converted into the methyl ester with diazomethane and then subjected to chromatography on silica gel which causes the methyl ester to lactonize,
- the epoxy lactones (VII) are then subject to treatment with lithium aluminum hydride at low temperature to form diol epoxides (VIII). These epoxide derivatives are treated with a dialkyl alkynyl aluminum derivative A to form the various acetylenic derivatives (IX) of this invention.
- Z' lower Alkyl, preferably CH 3 or C 2 H 5 ;
- X H or F;
- T' is lower alkyl from 3 to 6 carbon atoms, for example butyl or pentyl; and
- Y' is an alcohol protecting group for example, lower alkyl, such as tert-butyl .
- the resultant triols IX may then be oxidized with oxygen in the presence of a noble metal catalyst, such as Pt, to form the lactones X,
- a noble metal catalyst such as Pt
- the lactones may then be reduced with a hydride reagent such as diisobutylaluminum hydride at low temperature to form the hemiacetals of this invention XI which, when treated with the ylid prepared from 5-triphenylphosphonio-pentanoic acid yield after removal of the t-butyl protecting group with trifluoroacetic acid the 10,10-difluoro-13-dehydroprostaglandins XII of this invention, which are new products of this invention.
- a hydride reagent such as diisobutylaluminum hydride
- the above prostaglandins of structure XII can then be treated with a diazo-alkane, such as CH 2 N 2 and the resulting ester derivates cyclized by treatment with a halogen or halogenimide such as iodine and sodium bicarbonate to form the iodo ethers XIII.
- a base such as for instance diazabicyclo[5,4,0] undec-5-ene results e formation of the prosta- cyclins XIV and thei -isomers XV in the form of their esters which form physiologically active end products of this invention. Additional physiologically active products are formed by hydrolysis of the esters with sodium hydroxide, which gives rise to the corresponding sodium salts XIV and XV, respectively.
- further object of this invention is the production of the 10 ,10-difluoroprostaglandins and the 10,10-difluoro- prostacyclins possessing a trans-double bond in place of the acetylenic bond present in the compounds heretofore described.
- the synthesis of these compounds starts with the triol-t-butyl ethers IX. Removal of the t-butyl protecting group with trifluoroacetic acid and anisole gives rise to the tetrol IXc, in which the triple bond may now be reduced with lithium aluminum hydride to form the allylic alcohol XVI.
- the difluoro-lactones (Compounds 1A may be prepared in accordance with the procedures set forth hereinabove. In order to prepare the tetrafluoro (Compounds IC) or the difluoro-analogs (Compounds IB), the following procedure may be employed.
- Compounds 2 may then be treated in accordance with the procedures set forth herein and treated with a substituted triphenylphosphonioalkanoic acid (Compounds 3) to yield the corresponding prostaglandin (PGF) compounds (Compounds 4) .
- the known difluoro acid 1A will be converted into the anhydride 2A with acetic anhydride and the anhydride opened selectively with an alcohol e.g., methanol to form the monomethyl ester 3A.
- an alcohol e.g., methanol
- the latter will be reduced with a borohydride, e.g., NaBH 4 to the alcohol acid 4A.
- Compound 4A may then be treated with (CF-.SO-,) somebody0 and pyridine to obtain the triflate 5A which can be converted into the triphenylphosphonio derivative with triphenylphosphine .
- the latter will be hydrolyzed with acid to form the phosphonio acid salts 7A which may be employed for the synthesis of the compounds 4.
- the other triphenylphosphonio reactants which are employable in the practice of this invention to yield the 5-fluoro substituted final products, may be prepared in accordance with the following procedure:
- the difluorophosphonio acid 7A or its hydrogen analog 7B is treated with dimsyl sodium and FC10 3 to form the corresponding 5-fluoro derivatives, 8A and 8B which may be employed for the synthesis of yet additional compounds 4
- the resultant prostaglandin compounds 4 may then be further treated in accordance with the process of this invention to yield the desired prostacyclin compounds of the invention.
- the prostaglandin compounds may be treated as follows: Compounds 4 will then be further treated with I 2 or an active halogen compound such as N-bromosuccinimide or N-bromodimethylhydantoin to give the compounds 9 usually as a mixture of diaestereomers which will be separated.
- the major product will be treated with a base, e.g., DBU as detailed herein followed by alkaline hydrolysis to give the end products, the 5-fluoro; 4,4-, 7,7-difluoro; 4,4,5-, 7,7,5- 10 ,10 , 5-trifluoro; 4,4,7,7-, 7,7,10,10-, 4,4,10,10-hexafluoro and 4,4,5,7,7,10,10- heptafluoroprostacyclin sodium salts 5.
- a base e.g., DBU as detailed herein followed by alkaline hydrolysis to give the end products, the 5-fluoro; 4,4-, 7,7-difluoro; 4,4,5-, 7,7,5- 10 ,10 , 5-trifluoro; 4,4,7,7-, 7,7,10,10-, 4,4,10,10-hexafluoro and 4,4,5,7,7,10,10- heptafluoroprostacyclin sodium salts 5.
- diethyl 2-ketoglutarate (Compound a) is converted into diethyl 2 ,2-difluoro-glutarate (Compound b) by treatment with SF. is methylene chloride.
- Compound b is then selectively reduced with a borohydride, for example, sodium borohydride, to yield the alcohol acid (Compound C) , which may then be oxidized, for example, by the Moffatt-Pfitzner method using DMSO-oxalyl chloride to obtain the aldehyde ester (Compound d) .
- Compound d is then converted into Compounds 4 by treatment with the ylid compound (Compound e) in a Wittig reaction.
- Compounds 1 are treated in accordance with the procedures set forth hereinabove in the production of Compounds IXa - IXd, to yield the corresponding poly- fluorinated substituted derivatives (Compounds f_) .
- Compounds f are then reacted with a triaryl chloro- methane, for example, triphenyl chloromethane in pyridine to form the ether
- Compounds g which are then treated with an acylating agent, such as, acetic anhydride in pyridine to yield the diester Compounds h.
- the diesters are then reacted with a dilute organic acid, for example, 90% acetic acid to yield the alcohol Compounds i, which may then be treated with a sulfonating agent, for example, methane sulfonyl chloride in a base, such as pyridine to yield the sulfonated es.ter Compounds j.
- a sulfonating agent for example, methane sulfonyl chloride in a base, such as pyridine
- a base such as pyridine
- These sulfonated Compounds j may then be halogenated by reaction with a metal halide, for example, lithium bromide to yield the corresponding bromide Compounds k.
- Compounds k may then be treated with a phosphine, such as, triphenyl phosphine to yield the desired acylated phosphonium compounds, which may then be hydrolyzed by treatment with a mild mineral acid, such as hydrochloric acid to yield the corresponding dihydroxy phosphonium compounds, which are then reacted with a strong base, such as butyl lithium to yield the desired ylid compound (Compound e) , which may then be employed to obtain the desired prostaglandin compounds (Compounds 4) of this invention, as hereinbefore described.
- a phosphine such as, triphenyl phosphine to yield the desired acylated phosphonium compounds
- a mild mineral acid such as hydrochloric acid
- a strong base such as butyl lithium
- the invention may be further illustrated by the following examples.
- FC10 3 A stream of FC10 3 , purified by passing successively through 2N NaOH solution, 5% Na 2 S 2 O 3 solution and methanol was bubbled at 20° through a solution of 2 g (14.5 mole) of 4-allylcyclopentane-l,3-dione (lib) in 360 ml of methanol containing 3,19 g (31,9 mole) of KHCO-- until the reaction mixture was neutral.
- the reaction proceeds with formation of a white precipitate of KC10 3 , Excess FC10 3 was removed by bubbling N 2 through the mixture. Toluene (50ml) was added and the methanol was evaporated under reduced pressure.
- the organic layer was washed successively with 15 ml of 3M NaOH, 15 ml of 4N HC1, 10 ml of saturated NaCl and 10 ml of 3M NaOH. The organic layer was then dried and evaporated. The residue was placed on 50 g silica gel and the column washed with 500 ml of benzene, which completely eluted the compound added as stabilizer to tetrahydrofuran. The column was then washed with a further 1 liter portion of benzene containing 10% ethyl acetate and the solvents evaporated in vacuo. The residue was rechromatographed on 350 g of silica gel.
- the aqueous layer was then extracted with 400 ml (200 + 100 + 100 ml) of ethyl acetate, and the organic layer washed with 15 ml (10 + 5 ml) of water containing little Na 2 SO 3 and KI .
- the ethyl acetate layer was dried over anhydrous Na 2 SO 4 , evaporated and finally azeotroped with benzene for 1 1/2 hrs in a flask fitted with a Dean stark water separator. All the benzene was evaporated and the crude residue was chromatographed on 100 g of silica gel.
- Fractions 59 through 110 contained
- Trifluoromethanesulfonic anhydride (.825 ml, 4.09 mmole) was added through a syringe over a period of 3-4 min, to a solution of 610 mg (3.43 mmole) of all cis-1,1- difluoro-2,5-dihydroxy-3-carboxymethylcyclopentane
- the mixture was brought to room temperature and most of the pyridine was evaporated by a stream of N 2 .
- the last trace of pyridine was evaporated with 8 ml of benzene and the residue was extracted with 24 ml (3x8 ml) of benzene.
- the benzene extract was evaporated and the crude triflate was taken up in 4 ml of pyridine and refluxed for 12 min.
- the mixture was cooled and poured into 20 ml of 4N HCl and extracted with 160 ml (2x80ml) of benzene.
- the benzene layer was washed with 10 ml of water, dried and evaporated.
- Pieces of dry ice were added to lower the pH to 8-9, followed by solid iodine in one portion (400 mg, 1.57 mmole, 14 fold excess).
- the contents were strirred at room temperature (24°) for 14 hours in the dark, the methanol evaporated (N 2 ) , ethyl acetate (2 ml) added and evaporated (N 2 ) .
- the residue was dissolved in ethyl acetate (8 ml) and washed successively with saturated NA 2 SO 3 , water and brine. Removal of ethyl acetate after drying (MgSO 4 ) gave the iodolactone Via as a sticky solid (34.9 mg, quantitative).
- the crude product was crystallized from CHCI 3 (0.7-0.8 ml) at 60° to give colorless crystals (15.5 mg , 44.5%).
- the aqueous solution was extracted with 70 ml (40 + 30 ml) of ethyl acetate, the ethyl acetate layer treated with diazomethane and evaporated. The residue was taken up in chloroform, separated from insoluble matter and evaporated to give 29.5 mg of crude compound which is mostly all cis-1 ,1-difluoro- 2-hydroxy-3-carboxymethyl-4,5-epoxycyclopentane methyl ester. This compound was dissolved in little benzene and poured on to 9 g silica gel. After 20 hrs the column was eluted with 100 ml of benzene.
- Example 14 (2R,3R,4S,5S)-1,1-Difluoro-2-hydroxy-3[2'-hydroxyethyl]- 4 ,5-epoxycyclopentane (Villa). Following the procedure of Example 13 but substituting the [2S ,3S ,4R, 5R-lactone Vila for the racemate there is obtained the title compound (Villa). M p 59-59.5°; [ ⁇ ] D 25 -23° (CHCl 3 ).
- Example 18 (8S,9S,llR,12R,15S)-l,2,3,4,5-Pentanor-6,9,ll,15- tetrahydroxy-10,10-difluoro-13-prostyne-15-tert-butyl ether (IXc) Following the procedure of Example 16 but substituting the diol epoxide Vlllb for the racemate there is obtained the title compound (IXc). [ ⁇ ] D 25 +29.5°
- Example 21 (15S ) -1 , 2 , 3 , 4 , 5-Pentanor-9,11,15-trihydroxy-10,10- difluoro-13-prostyn-6-oic acid 6,9-lactone 15-tert butyl ether (Xa) + (Xc) .
- the test tube containing the triol was therefore rinsed with an additional 6 ml of acetone and this solution was also added.
- Into the reaction mixture was bubbled O 2 with stirring and heating at 58° for 5 hrs. It was then passed through a pad of celite (15 g), and washed repeatedly with EtOAc. The aqueous layer was separated and concentrated in vacuum to 6-7 ml, saturated with NaCl and extracted again with EtOAc. The combined EtOAc extracts were washed with brine, dried (Na 2 SO 4 ) and evaporated to yield the crude title compound Xa + Xc as a yellow gum. It was purified by tic, and yielded 41.7 mg of pure reaction product, (75%).
- Example 22 (8R, 9R, US , 12S , 15S) 1,2,3,4, 5-Pentanor-9,ll,15-trihydroxy- 10,10-difluoro-13-prostyn-6-oic acid 6,9-lactone 15- tert butyl ether (Xa) .
- Example 24 (8R,9R, US, 12S,15S,16S)-1,2,3,4,5-Pentanor-9,11,15- trihydroxy-10,10,16-trifluoro-13-prostyn-6-oic acid 6,9-lactone 15-tert butyl ether (Xb) Following the procedure of Example 21 but substituting the trifluoro triol IXb for the triol IXa + IXc there is obtained the title compound (Xb) .
- Example 28 (8S,9S,11R,12R,15S)-1,2,3,4,5-Pentanor-9,11,15- trihydroxy-10,10-difluoro-13-prostyn-6-al hemiacetal 15-tert butyl ether (XIc). Following the procedure of Example 26 but substituting the lactone Xc for the lactone Xa + Xc there is obtained the title compound (XIc) . [ ⁇ ] D 25 -39.0 (CHC1 3 ).
- Example 30 (8S,9S,llR,12R,15S,16S)-l,2,3,4,5-Pentanor-9,ll,15- trihydroxy-10,10,16-trifluoro-13-prostyn-6-al hemiacetal 15-tert butyl ether (Xld), Following the procedure of Example 26 but substituting the lactone Xd for the lactone Xa + xc there is obtained the title compound (Xld).
- the Na 2 CO 3 layer was acidified with cold 10% HCl to pH 1 and extracted repeatedly with EtOAc.
- the EtOAc extract was washed with brine, dried, (Na 2 S0 4 ) and evaporated to yield 18.2 mg of a yellow gum, which was purified by tic.
- the weight of pure 10 10-difluoro-13-dehydro-PGF.
- Example 44 10,10,16-Trifluoro-5-iodo-9-deoxy-6,9-oxido-13-dehdyro- prostaglandin F 1 ⁇ Methyl ester (Xlllb). Following the procedure of Example 41 but substituting the trifluoro compound Xlld for the difluoro compound XIIc + XIIi there is obtained the title compound (XHIb).
- Example 46 10 , 10-Difluoro-13-dehydro prostacyclin Methyl ester (XlVa) + (XlVe) and its ⁇ 4 -Isomer (XVA) + (XVe) .
- Example 47 10 ,10-Difluoro-13-dehydro prostacyclin Methyl ester (XlVa) and its ⁇ 4 -isomer (XVa) .
- Example 49 10,10 ,16-Trifluoro-13-dehydroprostacyclin Methyl ester (XIVc) and its ⁇ 4 -isomer (XVe) .
- XIVc Trifluoro-13-dehydroprostacyclin Methyl ester
- XVe ⁇ 4 -isomer
- Example 52 10-Difluoro-13-dehydroprostacyclin sodium salt (XlVb) Following the procedure of Example 51 but substituting the methyl ester XlVa for the mixture XlVa + XlVe there is obtained the title compound (XlVb) .
- Example 53 10-Difluoro-13-dehydroprostacyclin sodium salt (XlVf) . Following the procedure of Example 51 but substituting the methyl ester XlVe for the mixture XlVa + XlVe there is obtained the title compound (XlVf).
- Example 54 10 ,10,16-Trifluoro-13-dehydroprostacyclin sodium salt (XlVd) .
- Example 56 10,10-Difluoro-13-dehydroprostacyclin (4E) -Isomer Sodium Salt (XVb) + (XVf) .
- XVb 10-Difluoro-13-dehydroprostacyclin
- XVf 10-Isomer Sodium Salt
- Trifluoroacetic acid (2.50 ml) was added in one portio to 146 mg of the t-butyl-triol-yne (IXa) cooled to 0-5°.
- the magnetically stirred solution was placed in a cold room at -15°, and the reaction followed by tic. After completion (4 hr), workup of the reaction was performed at 0-5° with addition of saturated Na 2 CO 3 solution (approx. 17 ml) until pH 10 followed by addition of 13 ml of MeOH. The contents were stirred at room temperature of 0.5 hr, 10% HC1 was added until the solution was neutral followed by addition of 50 ml of saturated NaCl solution.
- reaction vessel was cooled to 0-5° and 10% HC1 was added until the evolution of gas ceased followed by addition of 30 ml of saturated NaCl solution.
- the aqueous solution was extracted with EtOAc (8 X 50 ml) the EtOAc extracts washed with saturated NaCl solution (Ix) , and then dried over anhydrous Na 2 SO 4 . Filtration and removal of solvent under vacuum gave 40 mg (88%) of crude material.
- Example 63 (8R,9R,US,12S)-1,2,3,4,5-Pentanor-9,11,15-trihydroxy- 10,10-difluoro-13-prosten-6-oic acid 6,9-lactone (XVII), Following the procedure of Example 21 but substituting the tetrol-ene XVI for the triol-yne IXa + IXc there is obtained the title compound (XVII)
- Example 64 (8R,9RAlSfl2S,15SH,2,3,4,5-Pentanor-9,11,15-trihydroxy- 10,10-difluoro-13-prostyn-6-al hemiacetal (XVIII).
- Example 65 10-Difluoroprostaglandin F 2 ⁇ (XIX).
- Example 68 10,10-Difluoroprostacyclin (XXIIa). Following the procedure of Example 51 but substituting 10 , 10-difluoro-prostacyclin methyl ester XXII for the 13-dehydro methyl ester XlVa + XlVe there is obtained the title compound (XXIa) .
- Example 69 Following the procedure set forth in Example 16, but substituting equivalent amounts of either dimethyl- 3-t-butyloxy-l-nonynylalane, or dimethyl-3-t-butyloxy- 4-fluoro-l-nonynylalane for the dimethyl-3-t-butyloxy- 1-octynylalane the corresponding homologous derivatives are obtained.
- Example 70 2 ,2-Difluoroglutaric Anhydride.
- a solution of 5 g of 2 ,2-difluoroglutaric acid in 20 ml of acetic anhydride is refluxed for two hrs, 5 ml of the resulting solution is distilled off at ordinary pressure and the residual solution freed from acetic anhydride under reduced pressure.
- the resulting oil consists of 2 ,2-difluoroglutaric anhydride.
- Example 72 4,4-Difluoro-5-hydroxy-n-pentanoic Acid Methyl Ester, To a solution of 2 g of 2 ,2-difluoroglutaric acid 1-methyl ester in 20 ml of methanol is added at 25° 250 mg of sodium borohydride and the mixture allowed to remain at 25° for 2 hrs. The solution is diluted with water and acidified to pH 1 with IN HCl and the methanol removed in vacuo. The residual suspension is extracted with methylene chloride and the extract dried with sodium sulfate and evaporated to dryness in vacuo. The residual oil is treated with ethereal diazomethane until the yellow color persists and the ether is removed in vacuo. There remains behind the title compound.
- Example 73 4,4-Difluoro-5-triphenylphosphoniopentanoic Acid Hydrochloride.
- Example 74 5-Fluoro-5-triphenylphosphoniopentanoic Acid, To a solution of dimsyl sodium in 5 ml of dimethylsulfoxide prepared from 84 mg of sodium hydride is added 888 mg of 5-triphenylphosphonio- pentanoic acid hydrochloride in 15 ml of DMSO. Into this solution is bubbled at 25° purified perchloryl- fluoride until the solution is neutral. Water is then added and dilute HCl and the fluoroacid extracted with methylene chloride. The organic extract is dried over sodium sulfate and evaporated to dryness in vacuo leaving behing the fluoroacid.
- Example 75 4,4, 5-Trifluoro-5-triphenylphosphoniopentanoic Acid .
- Example 76 Following the procedure of Example 74 but substituting an equivalent amount of 4 ,4-difluoro-5- triphenylphosphoniopentanoic acid hydrochloride in the reaction there is obtained the title compound.
- Example 76 Following the procedure of Example 74 but substituting an equivalent amount of 4 ,4-difluoro-5- triphenylphosphoniopentanoic acid hydrochloride in the reaction there is obtained the title compound.
- Example 77 2 3-c ⁇ s-2-Hydroxy-3-Carboxydifluoromethyl- ⁇ 4 -cyclopentene 2,2'-Lactone Following the procedure of Example 76 but substituting an equivalent amount of 2 , 3-cis-2-hydroxy- 3-carboxydifluoromethyl- ⁇ 4 -cyclopentene 2,2'-lactone in the reaction there is obtained the title compound.
- the aqueous solution was extracted with 70 ml (40+30 ml of ethyl acetate, the ethyl acetate layer treated with diazomethane and evaporated. The residue was taken up in chloroform, separated from insoluble matter and evaporated to give 29.5 mg of crude compound which is mostly all cis-1,1-difluoro-2-hydroxy-3-carboxydifluoro methyl-4,5-epoxycyclopentane methyl ester. This compound was dissolved in little benzene and poured on to 9 g silica gel. After 20 hrs the column was eluted with 100 ml of benzene.
- Example 85 (15S)-1,2,3,4,5-Pentanor-6,9,11,15-tetrahydroxy-7,7- difluoro-13-prostyne 15-tert-butyl ether.
- Example 86 (15S)-1,2,3,4,5-Pentanor-9,11,15-trihydroxy-7,7,10,10- tetrafluoro-13-prostyn-6-oic acid 6,9-lactone 15-tert butyl ether.
- the test tube containing the triol was therefore rinsed with an additional 6 ml of acetone and this solution was also added.
- Into the reaction mixture was bubbled O 2 with stirring and heating at 58° for 5 hrs. It was then passed through a pad of celite (15 g), and washed repeatedly with EtOAc. The aqueous layer was separated and concentrated in vacuum to 6-7 ml, saturated with NaCl and extracted again with EtOAc. The combined EtOAc extracts were washed with brine, dried (Na 2 SO 4 ) and evaporated to yield the crude title compound as a yellow gum. It was purified by tic, and yielded 41.7 mg of pure reaction product.
- Example 87 (15S) -1,2,3,4,5-Pentanor-9,11,15-trihydroxy-7,7, - difluoro-13-prostyn-6-oic acid 6,9-lactone 15-tert- butyl ether. Following the procedure of Example 86 but substituting an equivalent amount of the triol of Example 85 in the reaction there is obtained the title compound.
- Example 88 (15S)-1,2,3,4,5-Pentanor-9,11,15-trihydroxy-7,7,10,10- tetrafluoro-13-prostyn-6-al hemiacetal 15-tert-butyl ether
- Diisobutyl aluminum hydride (141 ⁇ l) was added dropwise to a stirred solution of 29.4 mg of the lactone of Example 86 in 0.45 mg of toluene at -70° over a 30 second period and the reaction mixture stirred at this temperature for 1 hr.
- To the mixture was added dropwise a saturated Na 2 SO 4 solution.
- Example 89 (15S)-1, 2 ,3,4,5-Pentanor-9,11,15-trihydroxy-7,7,- difluoro-13-prostyn-6-al hemiacetal 15-tert-butyl ether Following the procedure of Example 88 but substituting an equivalent amount of the lactone of Example 87 in the reaction there is obtained the title compound.
- Example 88 was hemiacetal (25.0 mg) of Example 88 in 150 ⁇ l of DMSO was injected into the above solution of the ylide at 25°, followed by two rinsings of a total of 40 ⁇ l. The reaction mixture was then allowed to stir at room temperature for 1 hr, following which it was cooled in ice water and acidified with N/10 HCl, to a pH of 1.
- PGF 2 was 17.3 mg.
- the ether extract was washed with brine, dried (Na 2 SO 4 ) and evaporated to yield the crude title compound as a light yellow oil, which was purified by tic.
- the weight of the pure iodo compound was 5.8 mg (81%).
- Example 105 Following the procedure of Example 105 but substituting an equivalent amount of the 4,4 ,10 ,10-tetrafluoro compound of Example 103 there is obtained the title compound.
- Example 105 Following the procedure of Example 105 but substituting an equivalent amount of the 5 ,10 ,10-trifluoro compound of Example 104 there is obtained the title compound.
- Trifluoroacetic acid (2.50 ml) was added in one portion to 146 mg. of the t-butyl-triol-yne of Example 84 cooled to 0-5°. The magnetically stirred solution was placed in a cold room at -15°, and the reaction followed by tic.
- Lithium aluminum hydride (0.148 g, 4.10 mmole)
- the tetraol-yne of Example 46 45 mg, 0.15 mmole
- 1.5 ml of dry THF were placed in a round bottom flask fitted with a spiral reflux condenser and drying tube. The contents were heated at gentle reflux in an oil bath maintained at 70°, and the reaction followed by glc. After 4 hrs, the reaction vessel was cooled to 0-5° and 10% HCl was added until the evolution of gas ceased followed by addition of 30 ml of saturated NaCl solution.
- EXAMPLE 120 7,7,10,10-Tetrafluoroprostaglandin F 2 ⁇ . Following the procedure of Example 95 but substituting an equivalent amount of the 7,7,10,10-tetrafluoroprosta- glandin F 2 ⁇ tert-butyl ether of Example 119 there is obtained the title compound.
- EXAMPLE 138 1,2,3,4 ,5-Pentanor-6, 9 ,ll,15-tetrahydroxy-13-prostyne 15-tert-butyl ether 9,11-diacetate 6-mesylate
- the ether solution was washed several times with water, dried over sodium sulfate and evaporated to dryness in vacuo leaving the 6-trityl ether 9,11-diacetate 15-tert-butyl ether as an oily residue, which was now treated with 3 ml of 90% acetic acid at room temperature for 18 hrs.
- the mixture was then taken up in methylene chloride and extracted with bicarbonate to remove acetic acid.
- the organic phase was dried over sodium sulfate and evaporated to dryness in vacuo .
- EXAMPLE 140 1,2,3,4, 5-Pentanor-6,9,11,15-tetrahydroxy-7,7,10,10-tetra- fluoro-13-prostyne 15-terjb-butyl ether 9,11-diacetate 6-mesylate
- a solution of the acetate mesylate of Example 138 (75 mg) and lithium bromide (250 mg) in 5 ml of methyl ethyl ketone is refluxed for 4 hrs .
- the mixture is taken up in dilute sodium bicarbonate and methylene chloride, the organic phase washed with sodium bicarbonate , the solution dried with Na 2 SO 4 and the solvent evaporated in vacuo.
- the residual bromide (65 mg) is taken up in acetonitrile and after addition of an equivalent amount of PPH 3 is refluxed for 5 hrs. Removal of the solvent leaves the title compound.
- reaction mixture was then allowed to stir at 25° for 1 hr following which it was cooled in ice water and acidified with N/10 HCl to a pH of 1. Extraction with ethyl acetate yielded the title compound which was purified by tic .
- Example 84 Following the procedure of Example 144 but substitutin an equivalent amount of the 7,7 ,10 ,10-tetrafluoroprosty of Example 84 in the reaction there is obtained the title compound.
- Example 157 Following the procedure of Example 157 but substituting an equivalent amount of 4,4,10,10-tetrafluofo-PGF 2 ⁇ tert butyl ether of Example 144 in this reaction sequence there is obtained the title compound.
- the invention may be variously otherwise embodied within the scope of the appended Claims.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Composes de prostaglandines et prostacyclines substituees par le fluor dans une ou plusieurs des positions suivantes, 4, 4; 7, 7; 10, 10; et 5.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8339879A | 1979-10-10 | 1979-10-10 | |
US83398 | 1979-10-10 | ||
US10852579A | 1979-12-31 | 1979-12-31 | |
US108525 | 1979-12-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0037422A1 true EP0037422A1 (fr) | 1981-10-14 |
EP0037422A4 EP0037422A4 (fr) | 1982-01-26 |
Family
ID=26769247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19800902203 Withdrawn EP0037422A4 (fr) | 1979-10-10 | 1981-04-21 | Prostaglandines et prostacyclines substituees par le fluor. |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0037422A4 (fr) |
JP (1) | JPS56501319A (fr) |
DK (1) | DK251481A (fr) |
IT (1) | IT1132991B (fr) |
WO (1) | WO1981001002A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU642818B2 (en) * | 1991-05-23 | 1993-10-28 | Hughes Aircraft Company | Dual reflection scanning antenna system |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3176313D1 (en) * | 1980-12-09 | 1987-08-20 | Teijin Ltd | Novel halogenated prostacyclins, process for the production thereof, and pharmaceutical use thereof |
CH651033A5 (de) * | 1981-03-11 | 1985-08-30 | Hoffmann La Roche | Fluorprostacycline. |
ES511067A0 (es) * | 1981-04-02 | 1983-06-16 | Searle & Co | Procedimiento para preparar un derivado de prostaglandina. |
US4579958A (en) * | 1983-12-23 | 1986-04-01 | G. D. Searle & Co. | 5-fluoro-3-oxa-6,7-didehydro-PGI1 compounds |
US4616034A (en) * | 1985-02-28 | 1986-10-07 | G. D. Searle & Co. | 15(R)-5-fluoroprostacyclins, pharmaceutical compositions and anti-thrombotic method of use thereof |
JPH01102059A (ja) * | 1987-10-16 | 1989-04-19 | Asahi Glass Co Ltd | 6−フルオロプロスタグランジン誘導体 |
DE69502517T2 (de) * | 1994-02-17 | 1998-10-01 | Asahi Glass Co Ltd | Difluorprostacycline, Zwischenprodukte und Verfahren zu deren Herstellung |
IN2015DN02814A (fr) | 2012-10-26 | 2015-09-11 | Asahi Glass Co Ltd |
-
1980
- 1980-10-02 JP JP50258880A patent/JPS56501319A/ja active Pending
- 1980-10-02 WO PCT/US1980/001292 patent/WO1981001002A1/fr not_active Application Discontinuation
- 1980-10-13 IT IT25285/80A patent/IT1132991B/it active
-
1981
- 1981-04-21 EP EP19800902203 patent/EP0037422A4/fr not_active Withdrawn
- 1981-06-09 DK DK251481A patent/DK251481A/da not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO8101002A1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU642818B2 (en) * | 1991-05-23 | 1993-10-28 | Hughes Aircraft Company | Dual reflection scanning antenna system |
Also Published As
Publication number | Publication date |
---|---|
IT1132991B (it) | 1986-07-09 |
DK251481A (da) | 1981-06-09 |
IT8025285A0 (it) | 1980-10-13 |
JPS56501319A (fr) | 1981-09-17 |
EP0037422A4 (fr) | 1982-01-26 |
WO1981001002A1 (fr) | 1981-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0011591B1 (fr) | Dérivés de prostane, leur préparation et compositions pharmaceutiques les contenant | |
JPH06145085A (ja) | カルバサイクリン類似体類 | |
CS228916B2 (en) | Method of preparing new derivatives of 9 alpha,6-nitril | |
US4324730A (en) | Certain fluorine substituted PGI2 compounds | |
EP0037422A1 (fr) | Prostaglandines et prostacyclines substituees par le fluor | |
EP0159784A1 (fr) | Analogues à la carbacycline | |
EP0099538B1 (fr) | Carbacyclines, procédé pour leur préparation et leur utilisation comme médicaments | |
EP0051558B1 (fr) | Dérivés de la prostacycline, leur préparation et leur utilisation dans des médicaments | |
US3862979A (en) | 9-desoxy-prosta-5,9(10),13-trienoic acid derivatives | |
EP0130142B1 (fr) | Dérivés de prostacycline, procédé pour leur préparation et leur utilisation comme médicament | |
US4456768A (en) | Chemical synthesis | |
EP0013955B1 (fr) | Analogues de prostacycline, leurs intermédiaires, procédé pour leur préparation et des médicaments les contenant | |
CH617186A5 (fr) | ||
US4424376A (en) | Prostacyclin intermediates | |
FR2515650A1 (fr) | Derives de 3-fluoro cyclopenta (b) furan-2-one | |
DE2830478C2 (de) | Prostaglandin-Analoge | |
CH623570A5 (fr) | ||
Fried et al. | Certain fluorine substituted PGI 2 compounds | |
EP0063538B1 (fr) | Prostaglandines et prostacyclines, leurs préparations et applications pharmaceutiques | |
JPS61227544A (ja) | 新規[4.2.0]ビシクロオクタン誘導体 | |
AT392071B (de) | Neue prostacycline | |
US4123456A (en) | Novel 11-hydroxy-9-keto-5,6-cis-13,14-cis-prostadienoic acid derivatives | |
US4311644A (en) | Method for preparing 10,10-difluoro prostacyclin intermediates and new compounds produced thereby | |
SE415095B (sv) | Forfarande for framstellning av 8,12-diisoprostansyraderivat | |
DE2716075A1 (de) | Neue zwischenprodukte und verfahren zur herstellung von thromboxan-analoga |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): CH DE FR GB LU NL SE |
|
17P | Request for examination filed |
Effective date: 19810930 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19860226 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: FRIED, JOSEF |